Mari Asada

No ORCID on file · 4 papers in corpus · active 2014-2020

Study types

  • article 3
  • other 1

Condition tags

  • endometriosis 4
  • endometrioma 2
  • adenomyosis 1
article 2020
Use of selective PGE2 receptor antagonists on human endometriotic stromal cells and peritoneal macrophages
Molecular human reproduction ·doi:10.1093/molehr/gaaa077

Non-hormonal therapeutic strategies for endometriosis are needed. The aim of this study was to characterize the effects of prostaglandin (PG)E2 receptor inhibitors to explore their potential as novel therapeutic strategies for endometriosis…

article 2016
Differential micro ribonucleic acid expression profiling in ovarian endometrioma with leuprolide acetate treatment
Journal of Obstetrics and Gynaecology Research ·doi:10.1111/jog.13137

AIM: Micro ribonucleic acids (miRNAs) play an important pathological role in endometriosis. Leuprolide acetate, an analog of gonadotropin-releasing hormone, is widely used to treat endometriosis; however, the molecular mechanisms involved i…

article 2015
Differential mRNA expression profiling in ovarian endometriotic tissue with versus without leuprolide acetate treatment
Journal of Obstetrics and Gynaecology Research ·doi:10.1111/jog.12768

AIM: Leuprolide acetate, an analog of gonadotropin-releasing hormone (GnRH), regresses endometriotic tissue and reduces pain, resulting in clinical improvement upon treatment. The molecular mechanisms involved in the regression of endometri…

other 2014
Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice
European journal of pharmacology ·doi:10.1016/j.ejphar.2013.12.001

TAK-385 (relugolix) is a novel, non-peptide, orally active gonadotropin-releasing hormone (GnRH) antagonist, which builds on previous work with non-peptide GnRH antagonist TAK-013. TAK-385 possesses higher affinity and more potent antagonis…